Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Atypical Antipsychotics (Apr 2017)

Posted by Matt Breese on Apr 28, 2017

Find me on:

According to our recent payer coverage analysis for atypical antipsychotic treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters shows the increasing amount of restricted lives, either not covered or impeded by PAs or step edits, for health exchange and medicare formularies. The percentage of covered lives that are restricted by restrictive-to-label PAs also increased.


Source: MMIT data as of Q2 2017

Trends:  Recent news related to antipsychotic treatments shows an increasing attention to prescribing habits. Recent studies show the increasing "range" of antipsychotic products, with increasing on-label and off-label utilization. Another unique quality of this disease area is the rising use of social media by atypical antipsychotic manufacturers to connect with patients and prescribers.

To read the full Reality Check on atypical antipsychotics with key findings on clinical characteristics, antipsychotic drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing